Received Apr 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | Y015100 | — |
No side effects or symptoms reported. No Additional information provided. No Additional AE/ N; HCP called to report a patient received MMR II (03/01/2025) and then received VARIVAX 7 days later (03/07/2025) instead of the recommended 4-week interval.; This spontaneous report was received from a pharmacist and refers to a 26-year-old male patient. The patient's medical history, current conditions and concomitant medications were not reported. On 01-MAR-2025, the patient was vaccinated with Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II), (strength, dose, anatomical route of administration, lot # and expiration date were not reported); and then on 07-MAR -2025 (reported as 7 days later) instead of the recommended 4 week-interval (inappropriate schedule of product administration), the patient was vaccinated with Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) 0.5 mL (lot #Y015100 who had been verified to be a valid lot number, expiration date assessed and reported as 06-SEP-2026), both vaccines were administered as prophylaxis. No additional adverse events reported.
Sterile diluent